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Abstract 
Aims. To identify differences in clinical epidemiology, in‐hospital management and 1‐year outcomes among patients 
hospitalized for acute heart failure (AHF) and enrolled in the European Society of Cardiology Heart Failure Long‐
Term (ESC‐HF‐LT) Registry, stratified by clinical profile at admission. 
Methods and results. The ESC‐HF‐LT Registry is a prospective, observational study collecting hospitalization and 1‐
year follow‐up data from 6629 AHF patients. Among AHF patients enrolled in the registry, 13.2% presented with 
pulmonary oedema (PO), 2.9% with cardiogenic shock (CS), 61.1% with decompensated heart failure (DHF), 4.8% 
with hypertensive heart failure (HT‐HF), 3.5% with right heart failure (RHF) and 14.4% with AHF and associated 
acute coronary syndromes (ACS‐HF). The 1‐year mortality rate was 28.1% in PO, 54.0% in CS, 27.2% in DHF, 
12.8% in HT‐HF, 34.0% in RHF and 20.6% in ACS‐HF patients. When patients were classified by systolic blood 
pressure (SBP) at initial presentation, 1‐year mortality was 34.8% in patients with SBP <85 mmHg, 29.0% in those 
with SBP 85–110 mmHg, 21.2% in patients with SBP 110–140 mmHg and 17.4% in those with SBP >140 mmHg. 
These differences tended to diminish in the months post‐discharge, and 1‐year mortality for the patients who survived 
at least 6 months post‐discharge did not vary significantly by either clinical profile or SBP classification. 
Conclusion. Rates of adverse outcomes in AHF remain high, and substantial differences have been found when 
patients were stratified by clinical profile or SBP. However, patients who survived at least 6 months post‐discharge 
represent a more homogeneous group and their 1‐year outcome is less influenced by clinical profile or SBP at 
admission. 
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Introduction 
Acute heart failure (AHF) represents a broad spectrum of disease states, with heterogeneous clinical 
presentations, but commonly characterized by either a rapid onset or a progressive worsening of signs and 
symptoms, requiring immediate treatment and leading to urgent hospitalization.
1
 The initial clinical 
presentation is more heterogeneous than the simple description “de novo or worsening heart failure 
(HF)”, and includes several distinct phenotypes such as acutely decompensated HF (DHF), cardiogenic 
shock (CS), pulmonary oedema (PO), right HF (RHF), hypertensive HF (HT‐HF) and HF in the setting of 
acute coronary syndromes (ACS‐HF).2 In addition to clinical profile classification, several other 
classification schemes have been proposed by the European Society of Cardiology (ESC) guidelines, 
including classification based on the level of systolic blood pressure (SBP) at initial presentation in the 
emergency department
3
 and the most recent one with phenotypes based on clinical signs of congestion 
and/or hypoperfusion.
1
 The identification of more distinct entities with different clinical outcomes would 
help clinicians to address the immediate life‐threatening medical condition and to direct treatment 
strategies more correctly by targeting specific underlying conditions and precipitating factors
,4
 in order to 
create pathways for better care of the spectrum of AHF patients.  
 
Several large and well designed registries
5-12
 have been created in recent years to describe more 
accurately the demographic, clinical, and therapeutic characteristics of AHF patients. However, with very 
few exceptions,
12, 13
 the description of the clinical course of AHF from prior registries was mainly 
restricted to the inpatient phase or the initial weeks post‐discharge. Very often, these registries were not 
representative, being either a single country description, or having a limited number of centres or clinical 
settings.  
 
The ESC Heart Failure Long‐Term (ESC‐HF‐LT) Registry is a permanent registry14, 15 with 
systematic collection of 1‐year follow‐up data, capturing the whole spectrum of AHF patients.  
  
The aim of the present analysis of the ESC‐HF‐LT Registry was to identify differences in clinical 
characteristics, in‐hospital treatment and outcomes among AHF patients stratified according to well 
specified clinical profiles within the overall descriptor of AHF.
2
 
Methods 
Study design and clinical setting 
The ESC‐HF‐LT Registry is a prospective, multicentre, observational study of patients admitted to 
211 cardiology centres (Appendix S1) from 21 European and Mediterranean countries, all members of the 
ESC. The number of participating centres per country was chosen in relation to the population of the 
country (one centre/2 million people, but no more than 25 centres per country) and centre selection took 
into account the geographical distribution of each country. Moreover, the selection of centres allowed for 
a representation of each category of hospitals and hospital facilities according to the distribution of the 
different types of medical centres in the individual country, approximately 20% of which should consist 
of centres providing cardiac surgery, 30% that do not provide cardiac surgery but do provide 
interventional cardiology, and 50% community centres providing neither cardiac surgery nor 
interventional cardiology.  
 
Periodic consecutive enrollment has been used and patients were included ‘one day per week’. In this 
1‐year follow‐up analysis, patient data of the best 12 consecutive recruitment months for each country 
were used for the analysis. 
 
The survey was approved by each local Institutional Review Board according to the rules of each 
participating country. No data were collected before detailed information was provided to the patient and 
a signed informed consent was obtained. 
 
The EURObservational Research Programme (EORP) Department was appointed to coordinate the 
project operationally, providing support to the committees, national coordinators and participating 
centres, and overseeing the implementation of the survey. 
Patient population 
The ESC‐HF‐LT Registry included all outpatients with chronic HF seen at the clinics and those 
admitted to hospital for AHF from selected centres. In the present analysis, all patients admitted for AHF, 
either de novo, or worsening of pre‐existing HF, for whom intravenous (i.v.) therapy (inotropes, 
vasodilators, or diuretics) was needed, were included. There were no specific exclusion criteria, with the 
exception that all patients had to be older than 18 years.  
 
A diagnosis of AHF was made by the clinician‐investigators at initial presentation and required the 
presence of signs and symptoms of HF, evidence of cardiac dysfunction, and the need for i.v. therapy.
14, 15
 
Several training meetings were organized for the study investigators to assure consistency in definition 
and data collection, and for a random sample of 5% of centres, data source verification was performed by 
EORP monitors.  
 
Patients were classified into the following six clinical profiles by the clinician‐investigators at the time 
of presentation according to the 2008 ESC guidelines:
2
 DHF, CS, PO, RHF, HT‐HF and ACS‐HF (see 
Supplementary material online, Appendix S2). Another two classifications, including SBP at presentation 
(<85 mmHg, 85–110 mmHg, 110–140 mmHg and >140 mmHg)3 and a classification based on the 
presence of clinical signs of congestion and/or hypoperfusion (no congestion and no hypoperfusion; 
congestion without hypoperfusion; hypoperfusion without congestion; hypoperfusion and congestion)
1 
were used for reporting in‐hospital and 1‐year adverse outcomes.   
A follow‐up visit 12 months after the entry visit was used to collect information on morbidity and 
mortality. 
Data collection 
All data including demographics, medical history, clinical presentation, laboratory results, inpatient 
management and in‐hospital and 1‐year outcomes were collected by chart review and entered into a 
centrally managed online database using a web‐based electronic case report form. Automated electronic 
data checks were performed to prevent out‐of‐range or duplicate entries. 
 
In‐hospital outcome included all‐cause mortality. One‐year outcomes included 1‐year mortality, 1‐
year HF readmissions and 1‐year death or HF readmission. The cause of death was categorized as cardiac, 
vascular, non‐cardiovascular, and unknown.16 
Statistical analysis 
Continuous variables were reported as mean ± SD, or as median and interquartile range. Among‐
group comparisons were made using a non‐parametric test (Kruskal–Wallis test). Categorical variables 
were reported as percentages and compared using chi‐square test or Fisher's exact test if any expected cell 
count was less than 5. For categorical variables with more than two possible values, exact P‐values were 
estimated according to the Monte Carlo method. Univariable analysis was applied to both continuous and 
categorical variables.  
 
Baseline characteristics and type of treatments were reported by clinical profile classification. In‐
hospital and 1‐year post‐discharge outcomes were also reported stratified by clinical profile, SBP 
classification and congestion/hypoperfusion. Plots of the Kaplan–Meier curves for time to all‐cause death, 
time to HF hospitalization and time to all‐cause death or HF hospitalization were performed for each 
clinical profile and for each SBP category. In addition to unadjusted Kaplan–Meier curves, Cox 
proportional hazard models with multivariable adjustment by clinical relevant variables such age, gender, 
chronic kidney disease, chronic obstructive pulmonary disease and cancer, have been performed. 
 
Furthermore, for each outcome, Kaplan–Meier curves have been generated for a different time point 
(T0): moment of admission, 1 month post‐discharge, and 3, 6 and 12 months post‐discharge, and 
outcomes in each group were compared using log‐rank test. A Tukey's adjustment of log‐rank has been 
performed and all clinical profiles and SBP categories were pairwise compared for each time point and 
each outcome. 
 
A two‐sided P‐value of <0.05 was considered statistically significant.  
 
All analyses were performed using SAS statistical software version 9.4 (SAS Institute, Inc., Cary, NC, 
USA). 
Results 
From April 2011 to June 2015, 16 012 patients were enrolled in the ESC‐HF‐LT Registry. Of these, 
6629 patients (41.4% of the total database) were hospitalized with a primary diagnosis of AHF and 9383 
patients (58.6%) were ambulatory patients with chronic HF. At 1 year, 411 AHF patients were lost to 
follow up, representing 6.2% of the study population. Median follow‐up time was 378 (288–415) days. 
  
Clinical classifications 
Of the AHF patients enrolled in the registry, 13.2% presented with PO, 2.9% with CS, 61.1% with 
DHF, 4.8% with HT‐HF, 3.5% with RHF, and 14.4% with ACS‐HF. 
 
The variation in classifications by geographical area is depicted in Figure 1. Considering SBP 
classification, 1.9% of AHF patients presented with SBP <85 mmHg, 24.9% with SBP 85–110 mmHg, 
42.9% with SBP 110–140 mmHg, and 30.3% with SBP >140 mmHg. Phenotyping AHF patients by 
clinical signs of congestion/hypoperfusion showed four mutually exclusive categories: no congestion and 
no hypoperfusion (14.8%), congestion without hypoperfusion (69.7%), congestion and hypoperfusion 
(13.6%), and hypoperfusion without congestion (0.9%) (Figure 1).  
 
 
 
Figure 1. Classification of acute heart failure patients by geographical area. A: clinical profile classification by geographical area. B: 
systolic blood pressure (SBP) classification by geographical area. C: congestion/hypoperfusion classification by geographical area. 
ACS‐HF, acute heart failure and associated acute coronary syndromes; CS, cardiogenic shock; DHF, decompensated heart failure; 
HT‐HF, hypertensive heart failure; PO, pulmonary oedema; RHF, right heart failure.  
 
  
Baseline characteristics and clinical profiles on admission 
The group with PO had the highest proportion of patients older than 75 years, while the proportion of 
females was highest in RHF, HT‐HF and PO (Table 1).  
Table 1. Epidemiology and baseline characteristics by clinical profile at admission 
 
Overall  
(n = 6629)  
PO  
(n = 875)  
CS  
(n = 195)  
DHF  
(n = 4052)  
HT‐HF  
(n = 320)  
RHF 
 (n = 233)  
ACS‐HF 
 (n = 954)  
P‐value  
         
Age >75 years, % 34.0 42.0 31.8 34.9 32.5 35.2 23.7 <0.0001 
Male, % 63.0 56.9 60.0 65.2 50.0 54.1 66.7 <0.0001 
History, %         
Diabetes 39.1 42.1 33.8 37.9 35.6 39.9 43.2 0.0062 
Previous MI 53.6 52.1 60.0 48.1 37.8 21.0 90.1 <0.0001 
PCI 20.2 20.4 23.1 18.1 13.7 8.1 33.5 <0.0001 
CABG 9.5 8.7 5.6 10.7 5.3 7.3 8.4 0.0014 
PM 6.0 6.0 5.7 6.6 4.1 10.3 2.7 <0.0001 
CRT‐P 0.6 0.2 0.0 0.9 0.0 0.4 0.4 0.0674 
CRT‐D 3.0 1.9 1.5 4.2 0.0 2.1 0.4 <0.0001 
ICD 5.1 3.8 5.6 6.4 1.2 3.8 2.1 <0.0001 
Valvular surgery 5.3 4.4 3.6 6.6 2.5 12.0 0.5 <0.0001 
PAD 13.9 15.9 14.3 13.5 12.2 13.8 14.1 0.05267 
Stroke/TIA 12.0 13.6 16.4 11.5 14.4 9.4 11.8 0.0812 
VTE 4.3 4.1 6.6 3.9 2.8 9.9 4.9 0.0002 
CKD 26.3 26.7 29.2 28.1 22.9 28.7 18.2 <0.0001 
Hepatic dysfunction 7.8 7.5 14.3 7.9 3.7 20.1 4.6 <0.0001 
Cancer 4.8 5.5 4.6 4.9 5.9 6.4 2.5 0.0136 
COPD 19.1 19.7 16.4 18.9 17.6 29.2 17.9 0.0032 
Sleep apnoea 2.9 2.5 1.0 3.4 3.8 4.8 1.1 0.0007 
Parkinson's disease 1.1 1.1 2.0 1.0 0.9 0.0 1.3 0.4211 
Depression 7.1 8.9 12.3 6.4 7.5 8.1 6.9 0.0070 
Primary aetiology, %         
Ischaemic heart disease 56.5 58.4 68.2 50.2 31.5 16.3 97.2 <0.0001 
Hypertension 8.2 13.9 1.0 6.0 50.3 3.4 0.4 <0.0001 
Dilated cardiomyopathy 13.6 9.7 18.4 18.5 3.1 7.7 0.6 <0.0001 
Valve disease 11.8 11.2 5.1 14.2 6.9 27.0 1.1 <0.0001 
Other 5.2 2.9 6.1 5.3 2.5 36.5 0.3 <0.0001 
Precipitants, %         
Myocardial ischaemia 30.0 34.7 57.9 17.3 21.2 3.4 93.4 <0.0001 
AF 30.3 27.3 26.15 34.3 29.3 34.7 16.3 <0.0001 
Ventricular arrhythmias 7.1 5.8 18.9 6.2 5.3 2.1 11.1 <0.0001 
Bradyarrhythmias 3.6 2.4 9.2 3.3 4.7 3.8 4.2 0.0002 
Infection 20.0 22.1 24.6 21.4 11.8 22.7 13.2 <0.0001 
Uncontrolled HTN 16.5 26.5 5.6 9.6 81.5 6.4 23.1 <0.0001 
Noncompliance 5.8 6.8 4.1 6.4 8.1 2.5 2.3 <0.0001 
Renal dysfunction 18.5 18.4 25.1 19.5 17.2 18.9 13.5 0.0002 
         
Anaemia 15.7 14.1 16.4 19.2 13.1 26.1 12.9 <0.0001 
Iatrogenic 1.2 1.5 1.0 1.3 0.6 0.8 0.7 0.5343 
Other 8.3 8.9 10.2 8.7 11.5 15.0 3.0 <0.0001 
Table 1. Epidemiology and baseline characteristics by clinical profile at admission 
 
Overall  
(n = 6629)  
PO  
(n = 875)  
CS  
(n = 195)  
DHF  
(n = 4052)  
HT‐HF  
(n = 320)  
RHF 
 (n = 233)  
ACS‐HF 
 (n = 954)  
P‐value  
Clinical presentation         
New onset, % 29.3 38.7 40.0 18.8 51.1 27.9 56.4 <0.0001 
Worsening, % 70.6 61.3 60.0 81.1 48.9 72.1 43.6 <0.0001 
SBP, mmHg (median [IQR]) 130.0 
[110–150] 
140.0 
[120–161] 
95.0 
[80–120] 
130.0 
[110–140] 
170.0 
[150–
190] 
120.0 
[110–140] 
138.5 
[120–156] 
 
HR, b.p.m. (median [IQR]) 88.0 
[73–104] 
95.0 
[79–110] 
100.0 
[79–117] 
85.0 
[70–100] 
87.5 
[74–108] 
85.0 
[70–100] 
90.0 
[75–108] 
 
Pulmonary rales, % 73.6 93.7 77.9 72.1 66.7 53.2 67.7 <0.0001 
JVP >6, % 35.2 40.8 50.2 36.3 20.6 58.8 21.0 <0.0001 
Peripheral oedema, % 55.4 46.2 48.2 63.7 40.9 84.9 27.6 <0.0001 
Hepatomegaly, % 25.4 23.3 25.2 27.8 18.2 52.6 13.0 <0.0001 
S3, % 30.5 34.3 48.7 25.8 26.2 25.4 46.0 <0.0001 
Peripheral hypoperfusion, % 17.8 22.4 56.4 15.0 10.7 13.8 20.9 <0.0001 
Peripheral congestion, % 56.0 61.8 64.9 59.1 38.2 76.3 36.1 <0.0001 
Pulmonary congestion, % 73.6 93.7 77.9 72.1 66.7 53.2 67.7 <0.0001 
Congestion without 
hypoperfusion, % 
69.7 68.3 16.0 73.4 73.1 72.3 60.3 <0.0001 
Congestion and hypoperfusion, 
% 
13.6 19.5 54.8 10.5 1.9 12.1 15.7 <0.0001 
Hypoperfusion without 
congestion, % 
0.9 9.3 26.4 0.8 0.2 1.0 1.7 <0.0001 
No congestion and no 
hypoperfusion, % 
14.8 2.9 2.8 14.3 24.8 14.6 22.3 <0.0001 
Laboratory values         
Creatinine, mg/dL (median 
[IQR]) 
1.2 
[0.9–1.5] 
1.2 
[0.9–1.5] 
1.4 
[1.0–2.1] 
1.2 
[0.9–1.6] 
1.0 
[0.8–1.4] 
1.2 
[0.9–1.5] 
1.1 
[0.9–1.4] 
 
Sodium, mmol/L (median 
[IQR]) 
139 
[135–141] 
138 
[135–141] 
136 
[133–140] 
139 
[135–141] 
140 
[137–
142] 
138 
[134–141] 
139 
[136–141] 
 
Glycaemia, mg/dL (median 
[IQR]) 
110 
[93–150] 
128 
[100–188] 
124 
[100–179] 
106 
[90–138] 
110 
[93–150] 
105 
[91–147] 
120 
[98–171] 
 
Haemoglobin, g/dL (median 
[IQR]) 
12.7 
[11.2–
14.1] 
12.4 
[11.0–13.9] 
12.6 
[10.7–
14.0] 
12.6 
[11.1–
14.0] 
12.9 
[11.5–
14.1] 
11.7 
[10.2–
13.6] 
13.2 
[11.9–
14.4] 
 
BNP, pg/mL (median [IQR]) 
(available for 701 pts) 
765 
[355–
1398] 
969 
[516–1502] 
1719 
[692–
2134] 
805 
[376–
1492] 
493 
[218–
872] 
578 
[286–912] 
680 
[350–
1398] 
 
NT‐proBNP, pg/mL (median 
[IQR]) 
(available for 1599 pts) 
3825 
[1658–
8960] 
6044 
[2523–
12317] 
5000 
[2220–
9809] 
3872 
[1674–
8839] 
2125 
[982–
4510] 
2096 
[1023–
9970] 
2537 
[1114–
6364] 
 
Troponin, mg/L (median [IQR]) 
(available for 2895 pts) 
0.10 
[0.03–
0.37] 
0.10 
[0.04–1.0] 
0.77 
[0.08–
27.0] 
0.06 
[0.02–
0.20] 
0.10 
[0.02–
0.10] 
0.04 
[0.02–
0.10] 
0.35 
[0.30–
4.60] 
 
ECG         
AF, % 42.7 38.8 34.8 48.5 39.4 54.9 21.4 <0.0001 
         
QRS duration, ms (mean ± SD) 109.6 ± 30 107.1 ± 28 110.4 ± 31 113.1 ± 31 101.0 ± 
25 
105.6 ± 29 102.2 ± 26 <0.0001 
QT duration, ms (mean ± SD) 376.9 ± 72 378.3 ± 73 385.4 ± 67 380.8 ± 71 369.5 ± 
70 
362.2 ± 82 365.6 ± 74 <0.0001 
LBBB, % 15.0 18.6 16.7 16.3 9.8 5.1 10.3 <0.0001 
Echo         
Table 1. Epidemiology and baseline characteristics by clinical profile at admission 
 
Overall  
(n = 6629)  
PO  
(n = 875)  
CS  
(n = 195)  
DHF  
(n = 4052)  
HT‐HF  
(n = 320)  
RHF 
 (n = 233)  
ACS‐HF 
 (n = 954)  
P‐value  
EF, % (mean ± SD) 39.2 ± 
14.5 
39.9 ± 14.7 34.8 ± 
14.0 
37.3 ± 
14.3 
50.9 ± 
13.7 
49.1 ± 
13.3 
40.3 ± 
12.5 
<0.0001 
EF <40%, % 53.2 52.0 67.3 58.8 20.6 22.7 48.0 <0.0001 
EF 40–50%, % 25.2 24.9 18.0 22.6 26.1 31.3 34.4 <0.0001 
EF >50%, % 21.6 23.1 14.7 18.5 53.4 46.0 17.7 <0.0001 
Mitral regurgitation, % 45.9 41.0 42.8 47.8 36.2 31.0 49.6 <0.0001 
Tricuspid regurgitation, % 35.4 26.1 34.0 40.2 21.6 69.6 22.9 <0.0001 
         
 
ACS‐HF, acute heart failure and associated acute coronary syndromes; AF, atrial fibrillation; BNP, brain natriuretic peptide; CABG, 
coronary artery bypass graft; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRT, cardiac 
resynchronization therapy; CS, cardiogenic shock; DHF, decompensated heart failure; EF, ejection fraction; HR, heart rate; HT‐HF, 
hypertensive heart failure; HTN, hypertension; ICD, implantable cardioverter‐defibrillator; IQR, interquartile range; JVP, jugular 
venous pressure; LBBB, left bundle branch block; MI, myocardial infarction; NT‐proBNP, N‐terminal proBNP; PAD, peripheral 
artery disease; PCI, percutaneous coronary intervention; PM, pacemaker; PO, pulmonary oedema; RHF, right heart failure; SBP, 
systolic blood pressure; VTE, venous thromboembolism; TIA, transient ischemic attack. 
Ischaemic aetiology was common in patients with CS (68.2%), while valvular aetiology was most 
frequent in RHF patients (27.0%). Large variations in reported aetiologies were noted in patients admitted 
with DHF (Table 1). Patients admitted with HT‐HF and ACS‐HF had fewer co‐morbidities than patients 
with CS and RHF (Table 1).  
 
At presentation, SBP differed markedly among clinical profiles and varied from 101.9 ± 29 mmHg in 
CS patients to 168.3 ± 31 mmHg in HT‐HF patients. Patients with CS retained distinguishing clinical 
features in terms of low SBP and signs of hypoperfusion, while most of the clinical characteristics were 
similar in patients with PO and DHF. Patients presenting with RHF had a constellation of clinical signs, 
including jugular venous pressure >6, peripheral oedema and hepatomegaly. 
 
Haemoglobin level <12 g/dL was found in 39% of patients and was more frequently observed in 
patients admitted with RHF and CS. A significantly higher proportion of CS patients presented with 
baseline renal dysfunction (creatinine >1.5 mg/dL). Hyperglycaemia (blood glucose >120 mg/dL) at 
presentation was reported in 41% of patients and in more than half of patients admitted with PO, CS and 
ACS‐HF (Table 1).  
 
A more elevated level of natriuretic peptides was found in patients with CS and PO compared with 
other clinical profiles. High troponin levels on admission were a distinctive feature of patients with ACS‐
HF and were also common in patients with CS and PO (Table 1).  
 
The proportion of patients with atrial fibrillation (AF) varied widely between the clinical profiles, with 
the highest AF prevalence being documented in patients with RHF. A proportion of 26% of patients had 
QRS duration >120 ms. QRS duration was larger in patients with CS and DHF, and the prevalence of left 
bundle branch block was highest in PO patients. Particularly, for patients admitted with CS, a longer QT 
interval duration was noted (Table 1).  
 
During hospitalization, echocardiography was performed in 78.3% of patients. A proportion of 53.2% 
of patients had an ejection fraction (EF) <40%, 25.2% had EF 40–50% and 21.6% had EF >50%. Mitral 
regurgitation was more often detected in patients admitted with ACS‐HF, DHF and CS, while tricuspid 
regurgitation was common in patients admitted with RHF (69.6%) (Table 1).  
  
In‐hospital management 
The use of i.v. treatments and interventional procedures in the different clinical profiles are reported in 
Table 2. In clinical profiles consistent with more severe HF, such as CS and PO, coronary angiography, 
percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) and intra‐aortic balloon 
pump insertion were more frequently used.  
Table 2. Intravenous vasoactive therapies and interventions during hospitalization 
 
Overall  
(n = 6629)  
PO  
(n = 875)  
CS  
(n = 195)  
DHF  
(n = 4052)  
HT‐HF  
(n = 320)  
RHF  
(n = 233)  
ACS‐HF  
(n = 954)  
P‐value  
         
Intravenous therapies, %         
Inotropes 12.3 14.2 81.0 9.8 1.5 9.8 11.2 <0.0001 
Vasodilators 21.2 46.1 14.0 10.7 36.9 3.9 43.6 <0.0001 
Diuretics 81.7 96.4 78.2 81.3 73.3 80.5 73.47 <0.0001 
Interventions, %         
Coronary angiography 20.8 23.5 37.1 14.7 14.5 9.9 45.9 <0.0001 
PCI/CABG 9.8 10.8 25.7 4.1 5.0 0.8 33.9 <0.0001 
EPS 0.6 0.4 0.0 0.7 0.0 0.8 0.4 0.3255 
Transcatheter ablation 0.6 0.3 1.0 0.7 0.0 1.3 0.5 0.3063 
Right heart catheterization 1.9 0.3 3.1 2.4 0.6 4.7 0.4 <0.0001 
IABP 1.1 1.5 14.9 0.3 0.0 0.8 1.5 <0.0001 
CRT‐D* 6.8 7.9 4.5 8.5 5.3 3.1 2.0 <0.0001 
CRT‐P* 1.9 0.6 4.4 2.1 0.0 0.3 1.2 <0.0001 
ICD* 9.6 10.2 15.8 11.1 5.3 1.7 5.1 <0.0001 
         
 
ACS‐HF, acute heart failure and associated acute coronary syndromes; CABG, coronary artery bypass graft; CRT, cardiac 
resynchronization therapy; CS, cardiogenic shock; DHF, decompensated heart failure; EPS, electrophysiological study; HT‐HF, 
hypertensive heart failure; IABP, intra‐aortic balloon pump; ICD, implantable cardioverter‐defibrillator; PO, pulmonary oedema; 
RHF, right heart failure. 
* CRT‐D, CRT‐P and ICD are mutually exclusive terms.  
In‐hospital outcomes 
The highest rate of in‐hospital all‐cause mortality was noted in CS patients (36.1%) and the lowest in 
HT‐HF patients (1.8%) (Table 3). When patients were stratified by SBP at admission, the highest in‐
hospital mortality was observed in patients with SBP <85 mmHg (26.6%) and the lowest in patients with 
SBP >140 mmHg (2.7%). Considering the congestion/hypoperfusion classification, the highest mortality 
was noted in patients with presence of both congestion and hypoperfusion signs (16.5%) and lowest in 
patients without congestion and without hypoperfusion (1.7%). Most of the in‐hospital deaths were 
cardiac in origin.  
 
  
Table 3. In‐hospital outcomes 
 
Overall  
(n = 6629)  
PO  
(n = 875)  
CS  
(n = 195)  
DHF  
(n = 4052)  
HT‐HF 
(n = 320)  
RHF  
(n = 233)  
ACS‐HF  
(n = 954)  
P‐value  
         
All‐cause death, % 5.5 6.4 36.1 4.2 1.8 9.4 4.2 <0.0001 
Cardiac 80.3 80.3 90.0 76.6 83.3 72.7 82.5 0.2534 
Vascular 5.5 3.6 8.6 5.2 0.0 4.5 5.0 0.8346 
Non‐cardiovascular 10.4 14.3 1.4 12.9 16.6 13.64 7.5 0.1122 
Unknown 3.8 1.8 0.0 5.26 0.0 9.1 5.0  
Time in hospital, days (median [IQR]) 7 [4–11] 7 [5–11] 7 [2–13] 7 [4–10] 6 [3–9] 8 [5–13] 6 [4–11]  
NYHA class IV at discharge, % 2.6 3.2 8.2 2.8 0.9 1.9 1.3 <0.0001 
Body weight status at discharge, %         
Decrease >3 kg 22.2 23.4 28.3 23.8 20.4 25.7 13.5 <0.0001 
Decrease 0–3 kg 72.9 71.1 66.7 71.5 75.4 70.4 81.1 <0.0001 
Increase 4.8 5.3 5.0 4.7 4.1 3.9 5.4 0.8612 
WRF at discharge*, %  12.5 16.5 21.0 11.8 10.1 9.8 11.3 0.0001 
Hyposodaemia at discharge**, %  17.9 17.3 24.4 18.9 11.3 22.8 14.1 0.0002 
Increase BNP, % 14.4 5.3 25.0 14.4 14.3 20.0 10.0 0.0921 
Decrease BNP <40%, % 35.1 36.6 45.1 35.1 13.7 38.0 25.5 0.0439 
Increase NT‐proBNP, % 21.6 24.5 32.5 19.1 14.4 18.9 13.0 0.1319 
Decrease NT‐proBNP <25%, % 16.1 23.8 9.1 16.3 9.1 12.4 10.7 0.0921 
         
 
ACS‐HF, acute heart failure and associated acute coronary syndromes; BNP, brain natriuretic peptide; CS, cardiogenic shock; DHF, 
decompensated heart failure; HT‐HF, hypertensive heart failure; IQR, interquartile range; NT‐proBNP, N‐terminal proBNP; NYHA, 
New York Heart Association; PO, pulmonary oedema; RHF, right heart failure; WRF, worsening renal function.  
* Serum creatinine difference between hospitalization and discharge >0.3.  
** Na <135 mEq/L.  
For patients hospitalized with CS, of the total number of deaths during hospitalization, 49% occurred 
in the first 24 hours from presentation, while for patients with PO, 16.3% of deaths occurred in the first 
24 hours. For the remaining clinical profiles, the rate of death in the first 24 hours represented less than 
10% of total number of deaths occurring during hospitalization. 
 
Between admission and discharge, New York Heart Association (NYHA) class and clinical signs and 
symptoms suggestive of HF showed substantial variation (Figure 2).  
  
 
 
 
Figure 2. New York Heart Association (NYHA) class and clinical signs: variation between admission and discharge for each 
clinical profile. ACS‐HF, acute heart failure and associated acute coronary syndromes; CS, cardiogenic shock; DHF, decompensated 
heart failure; HT‐HF, hypertensive heart failure; PO, pulmonary oedema; RHF, right heart failure. 
Of patients discharged alive, worsening renal function was documented in 12.5% of patients, and it 
was reported more often in patients hospitalized for CS (21.0%). Patients classified as CS and RHF had 
more frequent hyponatraemia at discharge as compared with other clinical profiles (Table 3).  
One‐year outcomes 
One‐year mortality rate was 26.7% and 1‐year HF hospitalization was 25.9% (Table 4). 
Cardiovascular deaths represented 57.2% of total deaths in the overall population. Similar to in‐hospital 
mortality, the highest 1‐year mortality rate was observed in patients with CS (54.0%), low SBP at 
admission (34.8%) and in patients with both congestion and hypoperfusion (29.8%).  
  
Table 4. One‐year outcome rate by different classifications of acute heart failure 
A. Clinical profile 
classification 
Overall  
(n = 
6629)  
PO 
(n = 875)  
CS  
(n = 
195)  
DHF  
(n = 
4052)  
HT‐HF  
(n = 320)  
RHF 
(n = 
233)  
ACS‐HF  
(n = 954)  
P‐value  
In‐hospital mortality, % 5.5 6.4 36.1 4.2 1.8 9.4 4.2 <0.0001 
One‐year all‐cause death, % 26.7 28.1 54.0 27.2 12.8 33.9 20.6 <0.0001 
Cardiac 53.4 48.9 78.0 50.6 51.3 50.7 62.8 <0.0001 
Vascular 3.8 6.5 6.0 3.0 2.5 1.3 4.7 0.0970 
Non‐cardiovascular 12.4 14.3 4.0 13.5 17.9 13.7 6.8 0.0098 
Unknown 30.4 30.3 12.0 32.9 28.2 34.2 25.6  
One‐year all‐cause 
hospitalization, % 
44.4 39.7 43.4 48.1 34.4 48.3 35.7 <0.0001 
One‐year HF hospitalization, % 25.9 20.8 20.8 29.91 14.34 31.2 17.6 <0.0001 
One‐year all‐cause death and/or 
HF hospitalization, % 
42.3 40.6 61.6 45.4 22.9 50.7 32.3 <0.0001 
B. Systolic blood pressure 
classification 
Overall  
(n = 
6629) 
SBP <85 mmHg  
(n = 128) 
SBP 85–110 
mmHg  
(n = 1653) 
SBP 110–140 
mmHg  
(n = 2845) 
SBP >140 mmHg  
(n = 2003) 
P‐value 
In‐hospital mortality, % 5.5 26.5 8.71 4.7 2.6 <0.0001 
One‐year all‐cause death, % 26.7 34.8 29.0 21.2 17.4 <0.0001 
Cardiac 53.4 61.3 47.7 44.3 44.5 0.2294 
Vascular 3.8 0.0 2.7 4.1 3.1 0.4588 
Non‐cardiovascular 12.4 19.3 11.1 13.1 14.3 0.4141 
Unknown 30.4 19.3 38.3 38.5 38.0  
One‐year all‐cause 
hospitalization, % 
44.4 53.6 48.1 45.2 40.0 <0.0001 
One‐year HF hospitalization, % 25.9 33.7 31.7 25.7 21.6 <0.0001 
One‐year all‐cause death and/or 
HF hospitalization, % 
42.3 55.0 47.7 38.0 32.1 <0.0001 
C. Congestion/hypoperfusion 
classification 
Overall  
(n = 
6502) 
No congestion no 
hypoperfusion  
(n = 983) 
Congestion 
without 
hypoperfusion  
(n = 4562) 
Hypoperfusion 
without 
congestion  
(n = 66) 
Hypoperfusion 
and congestion  
(n = 891) 
P‐value 
In‐hospital mortality, % 5.5 1.7 4.1 13.6 16.5 <0.001 
One‐year all‐cause death, % 26.7 12.9 23. 18.5 29.8 <0.001 
Cardiac 53.4 43.7 41.5 70.0 63.4 <0.001 
Vascular 3.8 4.2 3.1 10.0 3.8 0.571 
Non‐cardiovascular 12.4 10.1 14.2 10.0 9.1 0.175 
Unknown 30.4 42.0 41.1 10.0 23.5  
One‐year all‐cause 
hospitalization, % 
44.4 38.7 44.3 51.9 49.2 0.004 
One‐year HF hospitalization, % 25.9 16.4 26.9 25.0 32.2 <0.001 
One‐year all‐cause death and/or 
HF hospitalization, % 
42.3 24.8 40.3 37.0 49.4 <0.001 
       
 
ACS‐HF, acute heart failure and associated acute coronary syndromes; CS, cardiogenic shock; DHF, decompensated heart failure; 
HF, heart failure; HT‐HF, hypertensive heart failure; PO, pulmonary oedema; RHF, right heart failure; SBP, systolic blood pressure. 
 
  
Figures 3 and 4 show the Kaplan–Meier curves for all‐cause mortality, and the combined event of all‐
cause mortality and HF hospitalization for AHF patients stratified by clinical profiles, at different time 
points (at admission, and 1, 3, 6 and 12 months post‐discharge). One‐year outcome rates of each clinical 
profile have been pairwise compared for each outcome at each time point (see Supplementary material 
online, Table S1). Adjusted Cox proportional hazard models for each outcome are presented in the 
Supplementary material online, Table S2. 
 
 
 
Figure 3. Kaplan–Meier curves for all‐cause death at different time points: at admission (A), and at 1, 3, 6, and 12 months post‐
discharge (B). ACS‐HF, acute heart failure and associated acute coronary syndromes; CS, cardiogenic shock; DHF, decompensated 
heart failure; HT‐HF, hypertensive heart failure; PO, pulmonary oedema; RHF, right heart failure.  
 
  
 
 
 
Figure 4. Kaplan–Meier curves for all‐cause death and heart failure (HF) re‐hospitalization at different time points: at admission 
(A), and at 1, 3, 6, and 12 months post‐discharge (B). ACS‐HF, acute heart failure and associated acute coronary syndromes; CS, 
cardiogenic shock; DHF, decompensated heart failure; HT‐HF, hypertensive heart failure; PO, pulmonary oedema; RHF, right heart 
failure.  
When analysis of Kaplan–Meier curves was performed between 6 and 12 months post‐discharge, all 
six clinical profiles have comparable 1‐year outcomes. Patients with CS showed the highest 1‐year 
mortality rate during hospitalization and the first month after discharge. Patients with HT‐HF and ACS‐
HF had the lowest 1‐year Kaplan–Meier mortality regardless of the time point of analysis. Kaplan–Meier 
curves performed without these two clinical profiles showed no significant differences in 1‐year all‐cause 
mortality between PO, DHF, RHF and CS patients, even from 1‐month post‐discharge (see 
Supplementary material online, Figure S1).  
 
A similar analysis has been performed for SBP categories (see Supplementary material online, 
Figures S2 and S3), showing that between 6 and 12 months post‐discharge there were no significant 
differences in subsequent 1‐year mortality among the four SBP categories.  
 
For 1‐year HF hospitalization, 6‐month post‐discharge analysis showed reduced differences among 
clinical profiles and SBP groups, and at 1‐year post‐discharge there were no differences in outcomes 
among all clinical profiles and SBP groups. 
  
Discussion 
The present analysis describes the classification of patients with AHF, covering the entire spectrum of 
patients with AHF. Classification of AHF patients may facilitate an early decision‐making regarding 
appropriate triage and targeted treatment of high‐risk populations. 
 
Although DHF was the most common clinical presentation, similar to other registries,
6-10, 14
 
considerable differences in the prevalence of clinical profiles have been found across geographical 
regions. Furthermore, when considering other classification schemes, such as the most recent one based 
on congestion and hypoperfusion, substantial geographical variability has been found. The explanations 
for these geographical differences may be ‘investigator‐related’ and ‘system‐related’. ‘Investigator‐
related’ differences reflect variations in interpreting the definitions and different cultural perceptions of 
severity with different thresholds for hospital admissions, whereas ‘system‐related’ differences are due to 
the absence of objective criteria for hospital admission, as well as differences in patterns of medical care 
across regions. In contrast to clinical profile and congestion/hypoperfusion classifications, the 
classification based on initial SBP shows less geographic variation supporting its larger applicability in 
clinical practice.  
 
Our analysis shows that different clinical profiles may have similar clinical presentations, making the 
2008 ESC clinical classification
2 
challenging. Similar to other studies,
17, 18
 an elevated SBP at admission 
and signs of pulmonary congestion are common findings at presentation in PO, DHF and HT‐HF patients, 
leading to misclassification and overlap between these AHF phenotypes.  
 
Patients with CS were significantly different from the other clinical profiles for all clinical 
characteristics and should therefore be considered separately.
19
 In CS patients, overall utilization of i.v. 
inotropes during hospitalization (81.0%) exceeds the proportion of patients presenting with hypoperfusion 
signs at admission (56.4%). However, clinical signs vary rapidly during presentation
20 
and for some CS 
patients, hypoperfusion signs may not be apparent at presentation and become manifest later during 
hospitalization, suggesting ongoing clinical worsening despite the use of initial therapies.  
 
Right HF was also distinguishable from the other scenarios in terms of clinical characteristics and 
high 1‐year readmissions (48.3%). The clinical picture is dominated by signs of systemic congestion 
(jugular venous pressure >6, peripheral oedema and hepatomegaly) resulting from impaired right 
ventricular filling and/or reduced right ventricular output.
21
 Furthermore, patients with RHF have many 
co‐morbidities, which may prevent the optimization of HF evidence‐based therapies. Addressing non‐
cardiac co‐morbidities may be particularly important, since a vast proportion of re‐hospitalizations are not 
HF‐related.  
 
The ESC‐HF‐LT Registry is one of the few registries to describe AHF in the setting of ACS, and its 
reported prevalence of 14.4% was similar to that found in the Italian IN‐HF Outcome registry.9 ACS‐HF 
patients present with clinical signs indicative of high left ventricular filling pressures (pulmonary rales, S3 
sound, mitral regurgitation murmur) suggesting the impact of acute ischaemia on diastolic and systolic 
properties of the left ventricle.  
 
The prevalence of moderate‐to‐severe mitral and tricuspid regurgitation is similar to that reported in 
previous registries.
12
 Different from chronic settings, the prevalence of mitral and tricuspid regurgitation 
may be overestimated in AHF. During hospitalization, the severity of functional regurgitation may 
decrease as a result of decongestive therapies.  
  
In‐hospital management 
The type and proportions of vasoactive medications, stratified by clinical profile, are similar to those 
reported by other contemporary registries,
5-10, 18
 except for i.v. inotropes. The ESC‐HF‐LT Registry shows 
a lower use of i.v. inotropes in non‐CS patients compared to previous registries.  
 
Although ischaemic heart disease is by far the most common aetiology of AHF, coronary angiography 
and PCI/CABG were performed only in 21% and 10% of patients. Furthermore, even in patients 
classified as ACS‐HF, coronary angiography and PCI/CABG were performed in 45.9% and 33.9% of 
patients, suggesting large variations in available facilities,
22 
as well as variations in guideline adherence 
across the participating centres.  
 
The proportion of patients with cardiac resynchronization therapy/cardioverter‐defibrillator implants 
is similar to other studies.
22
 Although guidelines do not recommend to implant devices during acute 
decompensation, several patients may derive benefit from in‐hospital screening targeting device 
implantation during hospitalization. Further research is necessary to clarify the optimal timing of device 
implantation during hospitalization or soon after discharge among AHF patients.  
In‐hospital outcomes 
The highest mortality rates were observed in patients with CS, in those with SBP <85 mmHg, and in 
patients presenting with both congestion and hypoperfusion signs. Notably, in‐hospital and 1‐year 
mortality in CS were higher than in the group with SBP <85 mmHg or in the group with both congestion 
and hypoperfusion signs, suggesting that general metabolic compromise and multi‐organ failure, 
characteristic of CS, have distinct pathways beyond SBP and hypoperfusion, and may be responsible for 
the excess mortality. 
 
For patients admitted with CS, 49% of in‐hospital deaths occurred in the first 24 hours from 
presentation, suggesting that early identification of hypoperfusion signs, as well as appropriateness of 
initial therapies, may be potentially life‐saving in this setting. 
 
NYHA class and residual congestive signs and symptoms at discharge varied across clinical profiles, 
indicating different entities with different responses to AHF therapies,
23
 and suggesting that future 
clinical trials in hospitalized HF patients should take into account phenotypic diversity.
24
 
One‐year outcomes 
Similar to previous registries,
25-28
 1‐year outcome rates of each clinical profile considered by the ESC‐
HF‐LT Registry remain unacceptably high, confirming that hospitalization for AHF represents a change 
in the trajectory of the disease process. This finding can be explained by the fact that in‐hospital 
therapeutic approaches to these patients have remained practically unchanged during the last few decades.  
In the ESC‐HF‐LT Registry, the proportion of cardiovascular deaths (57.5%) is lower than in the 
ESC‐HF Pilot study (66%) and lower than in the Italian IN‐HF Outcome registry (71%). 
 
Present data reveal that 20% of patients are discharged despite persistent signs and symptoms of HF. 
A negligible decrease or an increase in body weight suggest a possible failure to relieve clinical 
congestion during index hospitalization, which may potentially contribute to the high post‐discharge 
event rate in the registry. Furthermore, for some AHF patients, natriuretic peptide levels do not decrease, 
or decrease insufficiently during hospitalization. Although the complete mechanisms are unknown, an 
insufficient decrease or re‐elevation of natriuretic peptides during hospitalization suggests residual 
haemodynamic congestion as a result of suboptimal treatment.
29
 
  
The highest rate of 1‐year death was observed in patients admitted with CS, and the highest rate of 1‐
year HF re‐hospitalization was noted in patients with RHF. Patients with HT‐HF and ACS‐HF had the 
best survival during hospitalization and throughout the follow‐up. These patients presented with high or 
normal SBP, had a lower index of non‐cardiac co‐morbidities, and were discharged with minimal residual 
congestion, better NYHA class and better renal function when compared to other clinical profiles. 
Furthermore, identification of aetiological factors and precipitants, as well as aetiological treatment 
(coronary interventions or hypertension treatment) is easier in these two clinical profiles. 
 
Differences in 1‐year outcome among clinical profiles and SBP categories depend on the time of the 
analysis. In particular, when performed later after discharge, differences in outcome rates among clinical 
profiles tend to disappear, and all clinical profiles have comparable 1‐year outcomes between 6 and 12 
months post‐discharge. ACS‐HF and HT‐HF patients tend to equalize 1‐year mortality rate of CS patients 
after 6 months post‐discharge. A similar finding was found when 1‐year outcomes were compared among 
SBP categories, and after 6 months post‐discharge, no differences in 1‐year outcome were noted. 
 
This finding can be relevant for future clinical trials enrolling patients hospitalized for AHF at 
different time intervals post‐discharge. When testing a novel therapy during HF hospitalization or in the 
first months post‐discharge, the investigators should be aware of the differences in outcome rates among 
AHF clinical profiles or SBP categories.
30
 Patients who have survived 6 months post‐discharge represent 
a more uniform group, and their subsequent 1‐year outcome rate is less influenced by clinical profile or 
SBP classification at admission.  
Limitations 
Although AHF criteria and classification are well established in the ESC guidelines and provided to 
the investigators, the AHF diagnosis and clinical profile assignment were made at the point of care by 
each clinician‐investigator, without central confirmation, potentially resulting in incomplete or inaccurate 
classification. The reliability of classification (i.e. agreement between two or more study investigators) 
was not assessed in this study and needs further investigation. Absence of the restricting criteria to grade 
severity of pulmonary congestion may have resulted in inconsistent classification and overlap between 
PO and HT‐HF patients. 
 
There was no central committee to adjudicate the causes of death and type of re‐hospitalization. 
 
The registry included only patients from cardiology departments or specialized HF units, and the 
extent to which the findings from this study can be generalized to other populations is unclear. 
Conclusions 
The ESC‐HF‐LT Registry demonstrates the importance of systematic characterization of AHF patients 
during their in‐hospital course. Classifying AHF patients on the basis of clinical relevant data may 
mediate improvements in quality of care and outcomes. 
 
Rates of adverse outcomes in patients admitted for AHF remain very high, both in‐hospital and during 
the follow‐up period, and substantial differences were found when patients were stratified by clinical 
profile, SBP, or congestion/hypoperfusion phenotypes. However, differences in 1‐year outcome rates tend 
to diminish in the first few months post‐discharge, and 1‐year outcome rates of patients following 6 
months after discharge did not vary significantly by clinical profile or SBP at admission, suggesting 
extinction of the initial acute process leading to decompensation and homogeneity in the long‐term 
course. 
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